On November 14, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the "Notice on the Adjustment and Disposal of the Price of the Centralized Procurement of Amoxicillin and Other Drugs in the Guangdong Alliance" (hereinafter referred to as the "Notice").

It is worth noting that there are still 11 manufacturers and 20 specifications that refuse to reduce prices for rectification, including well-known pharmaceutical companies, including AstraZeneca, Sanofi, Eli Lilly and other foreign pharmaceutical companies, and their products include well-known brand drugs such as Plavix (clopidogrel bisulfate tablets), Iressa (gefitinib tablets), and Alimta (pemetrexed disodium for injection).

The "Notice" emphasizes that the relevant drugs that refuse to accept the price rectification requirements will be disqualified from being selected and the selected price will be disqualified, and will be transferred to the alternative catalog. The platform will increase price risk warnings, and the task volume of the centralized procurement agreement for related drugs of medical institutions will be cancelled. Medical institutions will give priority to purchasing other selected products with lower prices with the same generic name.

The Shanxi Provincial Notice shows that Sanofi's Plavix (clopidogrel bisulfate tablets), AstraZeneca's Iressa (gefitinib tablets), and Eli Lilly's Alimta (pemetrexed disodium for injection) all refused to make rectifications and were adjusted to the list of alternative drugs.

More products have accepted this round of price adjustments. According to the announcement, 69 drugs agreed to make rectifications and made price adjustments, and almost all of them are domestic companies.

According to the letter from the National Medical Insurance Administration, this is only the first batch of disposal drug lists. I believe that there will be a second and third batch in the future... Under the requirement of reasonable price difference, I believe that more drugs, especially original research drugs, will lose priority purchasing rights due to refusing to reduce prices.

Source: https://mp.weixin.qq.com/